Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only a small subset of patients. Current oral antiviral agents effectively suppress viral ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

To facilitate the achieving of the goal of “eliminating viral hepatitis as a major public health threat by 2030” set by the World Health Organization, the Chinese Society of Hepatology together with ...

Worldwide, hepatitis B is thought to be the second deadliest infection; about 5% of the global population are infection and it can lead to liver cancer. | Microbiology ...

Hepatitis B can lead to liver disease. But we can prevent and manage this viral infection. Here’s what we know about the ...

Phase III study results demonstrate that tenofovir is superior to adefovir in treating HBV infection. Tenofovir was approved by the FDA in August 2008 for the treatment of patients with hepatitis ...

The data included results from a Phase 3 study on Biktarvy’s efficacy in treating HIV and HBV co-infection, a Phase 2 study on a long-acting treatment regimen, and findings from the first HIV ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...